TY - JOUR
T1 - Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors
T2 - Biological correlates of clinical outcome
AU - Cattelan, A. M.
AU - Calabro', M. L.
AU - Aversa, S. M L
AU - Zanchetta, M.
AU - Meneghetti, F.
AU - De Rossi, A.
AU - Chieco-Bianchi, L.
PY - 1999/12
Y1 - 1999/12
N2 - The clinical response of AIDS-related Kaposi's sarcoma (KS) to highly active antiretroviral therapy (HAART), a combination of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase inhibitors, was studied in 11 patients, all but one with progressive KS. CD4 + cell counts, plasma HIV-1 RNA levels, and antibody titres to lytic ORF65 and latency-associated human herpes virus type 8 (HHV-8) proteins were determined in sequential samples. Six complete and three partial clinical responses were achieved in a median time of 6 and 3 months, respectively, and confirmed after a median time of 16 months on HAART. 2 patients showed disease progression. A consistent decrease in HIV-1 RNA levels, paralleled by an increase in CD4 + cell counts, was observed in all patients who showed complete or partial clinical response; HIV-1 RNA levels remained persistently high in the two patients who progressed, despite a change in HAART. HHV-8 antibody titres were generally higher in patients with mucosal/visceral involvement compared with patients with limited disease; a decrease in ORF65 antibody titre was significantly associated with a clinical response. These results indicate that HAART is effective for AIDS-related KS; the clinical response correlates with a decrease in plasma HIV-1 RNA levels, an increase in CD4 + lymphocytes, and a decrease in antibodies to ORF65 HHV-8 protein.
AB - The clinical response of AIDS-related Kaposi's sarcoma (KS) to highly active antiretroviral therapy (HAART), a combination of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase inhibitors, was studied in 11 patients, all but one with progressive KS. CD4 + cell counts, plasma HIV-1 RNA levels, and antibody titres to lytic ORF65 and latency-associated human herpes virus type 8 (HHV-8) proteins were determined in sequential samples. Six complete and three partial clinical responses were achieved in a median time of 6 and 3 months, respectively, and confirmed after a median time of 16 months on HAART. 2 patients showed disease progression. A consistent decrease in HIV-1 RNA levels, paralleled by an increase in CD4 + cell counts, was observed in all patients who showed complete or partial clinical response; HIV-1 RNA levels remained persistently high in the two patients who progressed, despite a change in HAART. HHV-8 antibody titres were generally higher in patients with mucosal/visceral involvement compared with patients with limited disease; a decrease in ORF65 antibody titre was significantly associated with a clinical response. These results indicate that HAART is effective for AIDS-related KS; the clinical response correlates with a decrease in plasma HIV-1 RNA levels, an increase in CD4 + lymphocytes, and a decrease in antibodies to ORF65 HHV-8 protein.
KW - HAART
KW - HHV-8 antibodies
KW - HIV-1
KW - Kaposi's sarcoma
KW - Protease inhibitors
UR - http://www.scopus.com/inward/record.url?scp=0032760627&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032760627&partnerID=8YFLogxK
U2 - 10.1016/S0959-8049(99)00161-6
DO - 10.1016/S0959-8049(99)00161-6
M3 - Article
C2 - 10673996
AN - SCOPUS:0032760627
VL - 35
SP - 1809
EP - 1815
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 13
ER -